RUNX1 and acute lymphoblastic leukemia: Chemotherapy can be tailored according to minimal residual disease (MRD) data in childhood T-ALL, although MRD in T-ALL may not be good enough to predict final outcomes in the same way that B-ALL can be targeted based on ETV6-RUNX1 or hyperdiploidy2,36.